Kornimate/medical-research-clean huggingface dataset:
proteomics study by serum and platelet with neurodegeneration disease patients

Conditions: Biomarker With Neurodegeneration Patients

Summary: using to method of proteomics, for aims to conquer intractable disease, try to access variety experiment. biomarker is necessary to develop new diagnosis method and target of treatment.

following seoul national university hospital institutional review board approval, obtain serum and platelet with neurodegeneration patients and control group visited the part of neurology, there'll be analysis to differentiate each other diseases use to method proteomics. biomarker will be screening via 1d/2d analysis, mass analysis, database searching- the mascot search tool, swiss-prot and etc.

Eligibility criteria:
inclusion criteria: * neurodegeneration patients and control group include dementia patients visited the part of neurology. * over the age of 18 * when participants can understand subject of this study * total point of mini mental state exam(mmse)should be under 26 include mci (mild cognitive impairment) and over gds score 3points. exclusion criteria: * under eighteen years of age * when participants cannot understand subject of this study * cannot accept this study
a cohort study on the clinical characteristics and prognosis of hiv/aids patients infected with sars-cov-2

Conditions: PLWH; Covid-19; Clinical Features; Prognosis

Summary: on february 11th, 2020, the international classification of viruses named the disease caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) as novel coronavirus (covid-19, covid-19 for short). at present, covid-19 has become a global pandemic. however, the persistent replication of hiv in plwh and the cellular immunodeficiency and persistent inflammation caused by it may have different effects on the susceptibility, severity and course of covid-19. several large cohort studies have found evidence of increased risk of hospitalization and death in patients with hiv and covid-19 co-infection. meanwhile, a meta-analysis of 22 studies shows that hiv infection is still an important risk factor for acquiring covid-19 infection, and it is associated with a higher risk of death in covid-19. in order to further clarify the clinical features and prognosis of hiv co-infection with covid-19 and explore its immune mechanism, so we will carry out the study.


Eligibility criteria:
inclusion criteria: * age 18-75 years old; patients diagnosed with hiv in accordance with the chinese aids diagnosis and treatment guidelines. exclusion criteria: * hypertension, diabetes and other metabolic related diseases; severe circulatory and respiratory diseases; patients with immune-related diseases and immunosuppressants; pregnant and lactating women.
automatic abdominal aortic aneurysm diameter measurement

Conditions: AAA - Abdominal Aortic Aneurysm

Summary: managing abdominal aortic aneurysms currently relies on diameter assessment with ultrasound. diameter reproducibility with two-dimensional ultrasound is challenging, and requires experienced operators. a novel automatic three-dimensional ultrasound system has the potential to facilitate more precise diameter measurements than two-dimensional ultrasound. this study aimed to assess the variance of abdominal aortic aneurysm diameter measurements among ultrasound novices and experts by comparing two-dimensional ultrasound with the three-dimensional ultrasound system in a clinical setting. ten patients under abdominal aortic aneurysm surveillance were examined by 29 ultrasound-operators: 13 experts and 16 novices. the experts were sonographers and physicians highly experienced in abdominal aortic aneurysm ultrasound, and the novices were medical students and junior residents with sparse ultrasound experience.


Eligibility criteria:
inclusion criteria: -patients with an abdominal aortic aneurysm \> 3 cm.

Keywords: ultrasound three dimensional ultrasound abdominal aortic aneurysm sonography 3d ultrasound
patients' guidance with onco-coaching and cankado on systemic chemotherapy for metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: this is a prospective, single arm, non-interventional project to evaluate the benefit/influence of individualized patient education and guidance with a web-based e-health platform called cankado on patient reported outcomes (pro) for patients with metastatic colorectal cancer. the focus will be on patient reported outcomes (pro), distress, quality of life (qol), global health status, complaints and therapy relevant decisions. all patients will be medically treated according to the standards. the experimental arm will include 40 patients. those patients will receive one initial coaching before start of therapy. further appointments for coaching will be scheduled depending on individual patient's need. during treatment period the patient is encouraged of joining therapy actively documenting his state of health and occurring health complaints via cankado to give the physician a better overview on the process of patient's health behaviour and preparing him for the next doctor-patient consultation.


Eligibility criteria:
inclusion criteria: * minumum age of 18 years * patient with metastatic colorectal cancer exclusion criteria: -
nutrition, physical activity, and cognition in breast cancer survivors

Conditions: Breast Cancer; Cognitive Impairment; Cognition

Summary: the purpose of this study is to examine the relationship between nutrition, physical activity and brain function in breast cancer survivors.

the current study will examine the potential relationships between physical activity, dietary intake, body composition and cognition in breast cancer cancer survivors and age-matched women without a previous cancer diagnosis. additionally, we will measure blood inflammatory markers to explore the relationship between lifestyle factors and inflammation. the study involves two, 1hr appointments at texas state university. the first visit will include cognitive testing and body composition assessment. participants will be given an activity monitor to wear for one week and a packet of questionnaires to complete at home. at the second visit, a fasted blood sample will be collected, and participants will complete a food frequency questionnaire.

Eligibility criteria:
inclusion criteria: * breast cancer survivors must have completed primary treatment (chemotherapy, radiation therapy or both) within past 60 months * age-matched controls must have no previous cancer diagnosis * female * no history of stroke, heart attack or transient ischemic attack * not currently pregnant; can speak, read, and write english * can attend all testing sessions * not blind or legally blind; nonsmoker * no current use of computer-based brain training games (e.g. lumosity ®, brainhq ®). exclusion criteria: * male * \ 70 years of age * breast cancer survivor \> 60 months from last treatment or currently undergoing primary treatment * breast cancer survivor never treated with chemotherapy and/or radiation * previous cancer diagnosis other than breast cancer

Keywords: nutrition physical activity breast cancer survivor cognition
proton radiation for resectable carcinoma of the pancreas

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to find out what effects, good and/or bad, proton radiation combined with chemotherapy and surgery has on you and your pancreatic cancer. this study will look at the side effects from the treatment and the quality of your life in relation to pain. it will also look at how the tumor responds to the combination of treatment with radiation, chemotherapy and surgery.

chemotherapy capecitabine on radiation days proton radiation over 6 weeks surgery 6 weeks after radiation completion adjuvant chemotherapy starting 2-8 weeks after surgery with gemzar

Eligibility criteria:
inclusion criteria: * pathologically confirmed adenocarcinoma of the pancreas. * patients must have marginally resectable disease. * patients with biliary obstruction must have adequate drainage prior to starting chemoradiation. exclusion criteria: * evidence of distant metastasis including peritoneal seeding and/or ascites. * previous irradiation to the abdomen that would compromise the ability to deliver the prescribed treatment. * prior surgical resection. * gastroduodenal obstruction

Keywords: pancreatic cancer proton radiation chemotherapy xeloda gemzar resectable surgery
a study of loxo-305 in chinese participants with blood cancer (including lymphoma and chronic leukemia)

Conditions: Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Lymphoma, Mantle-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia, Lymphocytic, Chronic, B-Cell

Summary: a study of the safety, side effects, and effectiveness of loxo-305 in chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. participation could last up to four years.


Eligibility criteria:
inclusion criteria * participants with histologically confirmed b-cell malignancy including: * mantle cell lymphoma (mcl) treated with a prior bruton's tyrosine kinase (btk) inhibitor containing regimen; * cll/sll treated with a prior btk inhibitor containing regimen; * other types of b-cell nhl * all participants must have disease requiring treatment, for cll/sll participants, at least 1 indication for treatment consistent with iwcll 2018 criteria is required * eastern cooperative oncology group 0-2 * adequate hematologic status, coagulation, hepatic and renal function exclusion criteria * lack of adequate wash-out period for investigational agent or anticancer therapy, major surgery, and radiotherapy prior to the first dose of study treatment * participants requiring therapeutic anticoagulation with warfarin * known central nervous system (cns) involvement by systemic lymphoma. primary cns lymphoma is excluded * significant cardiovascular disease * prolongation of the qt interval * test positive for human immunodeficiency virus (hiv) * current treatment with certain strong cytochrome p450 3a4 (cyp450 3a4) inhibitors or inducers and/or strong p-glycoprotein (p-gp) inhibitors * pregnancy or lactation * active second malignancy * prior treatment with loxo-305 * known hypersensitivity to any component or excipient of loxo-305
study of arbaclofen for the treatment of social withdrawal in subjects with autism spectrum disorders

Conditions: Autism Spectrum Disorders

Summary: to explore the efficacy, safety and tolerability of stx209 (arbaclofen) administered for the treatment of social withdrawal in subjects with autism spectrum disorders


Eligibility criteria:
inclusion criteria: * diagnosis of autism spectrum disorders (asd) * current pharmacological treatment regimen has been stable for at least 4 weeks prior to screening. * subjects with a history of seizure disorder must currently be receiving treatment with antiepileptics and must have been seizure free for 6 months, or must be seizure free for 3 years if not currently receiving antiepileptics. * if the subject is already receiving stable non-pharmacologic educational, behavioral, and/or dietary interventions, participation in these programs must have been continuous during the 2 months prior to screening exclusion criteria: * subjects with any condition, including alcohol and drug abuse, which might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. * subjects who plan to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study. * subjects who have taken another investigational drug within the last 30 days. * subjects who are not able to take oral medications

Keywords: asd autism asperger syndrome
pyronaridine-artesunate with low dose primaquine for preventing p. falciparum transmission

Conditions: Malaria,Falciparum

Summary: the purpose of this study is to assess the gametocytocidal and transmission reducing activity of pyronaridine-artesunate (pa) and dihydroartemisinin-piperaquine (dp) with and without a single low dose of primaquine (pq; 0.25mg/kg). outcome measures will include infectivity at 2 and 7 days after treatment, the duration of infectivity in the artemisinin combination therapy (act) only arms, and the production and detectability of histidine rich protein ii.

protocol will be shared on request

Eligibility criteria:
inclusion criteria: * age ≥ 5 years and ≤ 50 years * absence of symptomatic falciparum malaria, defined by fever on enrolment * presence of ≥16 gametocytes/µl (i.e. ≥1 gametocytes recorded in the thick film against 500 white blood cells) * no allergies to study drugs * use of antimalarial drugs over the past 7 days (as reported by the participant) * hemoglobin ≥ 9.5 g/dl * individuals weighing \>\< 80 kg * no evidence of severe or chronic disease * written, informed consent exclusion criteria: * age \ 50 years * pregnancy * previous reaction to study drugs/known allergy to study drugs * signs of severe malaria * taking drugs which may be metabolized by cytochrome enzyme cyp2d6 (e.g., flecainide, metoprolol, imipramine, amitriptyline, clomipramine) * blood transfusion within the last 90 days * patients with clinical signs or symptoms of hepatic injury (such as nausea and/or abdominal pain associated with jaundice) or known severe liver disease (i.e. decompensated cirrhosis, child-pugh stage b or c). * patients with clinical signs or symptoms of renal impairment or known renal impairment * family history of congenital prolongation of the qtc interval or sudden death or with any other clinical condition known to prolong the qtc interval such as history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease. * taking drugs that are known to influence cardiac function and to prolong qtc interval, such as class ia and iii: neuroleptics, antidepressant agents, certain antibiotics including some agents of the following classes - macrolides, fluoroquinolones, imidazole, and triazole antifungal agents, certain non-sedating antihistaminics (terfenadine, astemizole) and cisapride. * consent not given

Keywords: primaquine pyramax euartesim dihydroartemisinin-piperaquine pyronaridine-artesunate
effect of oxidant gel and anti-oxidant gel on wound healing after gingival depigmentation

Conditions: Gingival Pigmentation

Summary: to evaluate effect of oxidant (oxygen releasing oral gel) with coe-pak versus anti-oxidant (nano-emulsion complex propolis and vitamin c gel) with coe-pak on wound healing, pain, patient satisfaction after gingival depigmentation

gingival depigmentation is considered a periodontal plastic surgery, in which gingival hyperpigmentation is eliminated. the scalpel surgical method is one of the most cost-effective methods, easiest and does not need broad equipment. however, scalpel surgery leads to bleeding during and after surgery, and the surgical area has to be covered with periodontal dressing for 7-10 days. periodontal dressings are used around the necks of the teeth and surrounding tissue to cover the wound. non-eugenol dressings are now the most commonly used periodontal dressings include coe-pak, cross pack, peripac, septopack, periocare, perio putty and periogenix. anti-oxidant gel (nano-emulsion complex propolis and vitamin c - nbf gingival gel®) is a high efficiency nano bio fusion gel containing propolis, nano vitamin c, e and herb extract. anti-oxidant power of nano vitamin c (nbf gingival gel®) is ten times more effective in hundred times smaller amounts, than vitamin c by itself. vitamin c collaboratives with vitamin e and preserves cell membranes integrity. propolis has antioxidant effect due to its radical scavenging ability, which was more efficient than antioxidant effect of vitamin c. it also enhances synthesis of collagen due to the presence of iron and zinc elements. it has proven to increase healing of epithelial tissues. the presence of oxygen in oxygen releasing oral gel (blue®m gel) enhances cellular metabolism, collagen synthesis, antibacterial activity, angiogenesis, revascularization, and the release of growth factors, it also helps keratinized tissue formation and has antimicrobial effects.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years with anterior maxillary or mandibular physiologic gingival pigmentation * systemically healthy patients * good oral hygiene, plaque index less than 15%. * cooperative patients able and accept to come for follow up appointments exclusion criteria: * any interim intervention that may have affected any of the outcomes of interest. * pregnant and lactating females. * smokers * patients reporting systemic conditions that may cause hyperpigmentation (eg.addison's disease) or on medications (eg. corticosteroids) * patients reporting systemic conditions that may compromise healing (eg. diabetes) * patients with poor oral hygiene. * any known allergies

Keywords: oxidant gel anti-oxidant gel gingival depigmentation
an extension of the concert protocol (dim18)

Conditions: Alzheimer's Disease

Summary: an open-label extension study of the concert (dim18) protocol evaluating the safety of dimebon (latrepirdine) in subjects with with mild-to-moderate alzheimer's disease on donepezil.


Eligibility criteria:
inclusion criteria: * successful completion of the 12 month dim18 concert study * mild-to-moderate alzheimer's disease * probable ad, diagnostic and statistical manual of mental disorders-iv-text revised (dsm-iv-tr) * mini-mental state exam (mmse) score between 12 and 24, inclusive * stable on donepezil for at least 6 months exclusion criteria: * other causes of dementia * major structural brain disease * unstable medical condition or significant hepatic or renal disease
evaluating the impact of automated evaluation of gastrointestinal symptoms (aegis) on clinical outcomes

Conditions: Abdominal Pain; Deglutition Disorders; Fecal Incontinence; Nausea; Diarrhea; Constipation; Gastroesophageal Reflux

Summary: healthcare delivery now mandates shorter visits with higher documentation requirements, undermining the patient-provider interaction. electronic health records (ehrs) have the potential to improve outcomes and quality of care in this pressured environment, and are endorsed by the patient protection and affordable care act (aca) and health information technology for economic and clinical health (hitech) act as an important mechanism to support value-based healthcare. however, ehr systems were principally designed to support the transactional needs of administrators and billers, less so to nurture the relationship between patients and their providers. the purpose of this research is to identify ways to use ehrs to support clinical gastroenterologists and their patients while meeting the meaningful use requirements of the hitech act. to improve clinic visit efficiency and meet criteria for meaningful use, investigators developed a patient-provider portal (p3) that systematically collects patient symptoms using a computer algorithm called automated evaluation of gastrointestinal symptoms (aegis). aegis utilizes computerized adaptive testing (cat) to guide patients through questions drawn from a library of over 300 symptom attributes measuring the timing, severity, frequency, location, quality, and character of their gi symptoms, along with relevant comorbidities, family history, and alarm features. the system then automatically "translates" the patient report into a full narrative hpi available for use by gi providers in an ehr. in a cross-sectional study in the american journal of gastroenterology comparing aegis versus physician-documented hpis, investigators found that blinded physician reviewers perceived that aegis hpis were of higher overall quality, better organized, and more succinct, comprehensible, complete and useful compared to hpis written by physicians during usual care in academic gi clinics. in the current study, investigators aim to evaluate computer-generated hpis prospectively on a wider scale in diverse academic and community-based settings. moreover, investigators aim to test an enhanced aegis intervention that ties patient hpis to an individualized "education prescription" which guides the patient through a library of multi-media educational materials on gi symptoms, conditions, and treatments.


Eligibility criteria:
inclusion criteria: * presenting to the gastrointestinal clinic for evaluation. * able to read and write english. * has basic computing skills. exclusion criteria: * having been seen and evaluated in the gastrointestinal clinic within the last 8 months.
vitrectomy combined with intravitreal dexamethasone implant for idiopathic epiretinal membrane with macular oedema

Conditions: Epiretinal Membrane

Summary: the goal of this clinical trial is to evaluate the efficacy and safety of 25-gauge pars plana vitrectomy combined with intravitreal dexamethasone implant for the treatment of idiopathic epiretinal membrane with cystoid macular oedema. the main questions it aims to answer are: * mean changes in best corrected visual acuity and central macular thickness from baseline to post-operative 24 weeks * mean change in proportion of cystoid macular oedema area from baseline to post-operative 24 weeks * intraocular pressure throughout postoperative 24 weeks * concentrations of inflammatory factors in vitreous samples participants will undergo a standard three-port 25-gauge pars plana vitrectomy and epiretinal membrane peeling combined with phacoemulsification, aspiration, and intraocular lens implantation. the dexamethasone implant will be injected into the vitreous cavity at the end of the operation.


Eligibility criteria:
inclusion criteria: * symptomatic patients aged 40 years or above with idiopathic stage 3-4 epiretinal membrane defined on the basis of spectral-domain optical coherence tomography classification; * central retinal thickness \>300 µm; * cystoid oedema within a 1 mm diameter range with the macular fovea as the center; * ocular axial length less than 25.00 mm. exclusion criteria: * concomitant or previous macular diseases that may hinder visual improvement other than epiretinal membrane (e.g., age-associated macular degeneration, retinal vein occlusion, or diabetic macular oedema); * previous vitreoretinal surgery or intravitreal injection history; * history of glaucoma or optic neuropathy of any kind; * patients with uncontrolled systemic diseases or infectious diseases; * patients who took medicines that may have ocular side effects, such as glucocorticoid or hydroxychloroquine.